共 395 条
[1]
Roex G(2020)Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data Pharmaceutics 396 839-852
[2]
Feys T(2020)Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet 398 314-324
[3]
Beguin Y(2021)Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Lancet 20 31-42
[4]
Kerre T(2019)Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Lancet Oncol 384 705-716
[5]
Poire X(2021)Idecabtagene Vicleucel in relapsed and refractory multiple myeloma N Engl J Med 380 45-56
[6]
Lewalle P(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 382 1331-1342
[7]
Abramson JS(2020)KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma N Engl J Med 6 e521-e529
[8]
Palomba ML(2019)A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial Lancet Haematol 13 164-619
[9]
Gordon LI(2020)Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma J Hematol Oncol 27 616-1582
[10]
Lunning MA(2021)Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Nat Med 12 865-2866